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Abstract
Antimicrobials are critical to contemporary high-intensity beef production. Many different antimicrobials are
approved for beef cattle, and are used judiciously for animal welfare, and controversially, to promote growth and
feed efficiency. Antimicrobial administration provides a powerful selective pressure that acts on the microbial
community, selecting for resistance gene determinants and antimicrobial-resistant bacteria resident in the bovine
flora. The bovine microbiota includes many harmless bacteria, but also opportunistic pathogens that may acquire
and propagate resistance genes within the microbial community via horizontal gene transfer. Antimicrobial-resistant
bovine pathogens can also complicate the prevention and treatment of infectious diseases in beef feedlots,
threatening the efficiency of the beef production system. Likewise, the transmission of antimicrobial resistance
genes to bovine-associated human pathogens is a potential public health concern. This review outlines current
antimicrobial use practices pertaining to beef production, and explores the frequency of antimicrobial resistance in
major bovine pathogens. The effect of antimicrobials on the composition of the bovine microbiota is examined, as
are the effects on the beef production resistome. Antimicrobial resistance is further explored within the context of
the wider beef production continuum, with emphasis on antimicrobial resistance genes in the food chain, and risk
to the human population.
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Background
The emergence of antimicrobial resistance in bacterial
pathogens is a serious global issue. Antimicrobial use in
livestock, aquaculture, pets, crops, and humans selects
for antimicrobial-resistant (AMR) bacteria that reside in
agricultural and clinical biomes. Besides pathogens,
AMR bacteria include many harmless and beneficial
microbes acting as a genetic reservoir of AMR gene
determinants (‘the resistome’ [1, 2]), which can be
transferred via mechanisms of horizontal gene transfer
(HGT) (reviewed in [3]) throughout the microbial
community. With alarming frequency, untreatable
human and animal pathogens with multiple AMR deter-
minants arise. AMR in pathogens is commonly accepted
as a result of widespread use and abuse of antimicrobials
in agriculture and medicine. Although the use of anti-
microbials in livestock and aquaculture has attracted
particular attention, antimicrobials are also widely used
in companion animals and in plant agriculture (e.g.
oxytetracycline and streptomycin), for feed crops, and
for tomatoes, citrus, and many other fruits [4]. Here, the
focus is on large-scale beef production, where antimicro-
bials are routinely used to support animal welfare, and
controversially, to promote growth and production
efficiency. In this review, the usage of antimicrobials in
cattle will be summarized along with recent studies on
AMR explored within the context of the beef production
system.
Beef production
Worldwide, beef production is the third largest meat
industry (~65 million t globally), behind swine and poultry
[5]. In 2015, the major beef producing countries included
the United States (US) (11.4 million t), Brazil (9.6 million t),
the 28 member countries of the European Union (EU) (7.5
million t), China (6.7 million t), and India (4.5 million t)
(Fig. 1a) [6] with the global beef cattle population
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exceeding 1 billion [6]. Beef production is complex and
involves multiple stages, wherein calves are birthed,
raised and fed for slaughter, and processed for meat.
The raising of cattle in high-throughput production
typically involves the movement of animals from (I)
cow-calf systems (a permanent herd used to produce
young beef cattle), to (II) backgrounding (post-weaning
intermediate feeding, typically forage-based diets), and
(III) feedlot/finishing operations (concentrated animal
feeding, typically with high-energy grain-based diets).
After finishing, animals are transported to a slaughter-
house and processed. Antimicrobials may be given to live
cattle at any production stage for therapeutic and non-
therapeutic purposes.
Antimicrobial usage in beef production
Rationale for antimicrobial use
Antimicrobials are used in beef cattle for the therapeutic
treatment of infections caused by bacteria or other
microbes. Cattle can be afflicted by a variety of endemic
infectious diseases, which may exist ubiquitously in
the ranching environment [7]. Endemic pathogens often
go unnoticed, but compromise animal health—affecting
herd growth performance and farm profitability.
Infections spread rapidly in high-density feedlots, and
despite herd management procedures, both endemic and
exotic diseases can be introduced by importation of
diseased animals into the beef production system.
Globally, 4.7 million cattle are exported to beef produ-
cing countries, with the top exporters being Mexico,
Australia, and Canada, exporting >1.3, >1.2, and >1.0
million cattle, respectively. These cattle are sent primar-
ily to the US, which received >2.2 million cattle in 2015
[6]. The risk of disease transmission creates significant
economic pressure for antimicrobial usage to prevent in-
fectious bovine diseases.
Therapeutic and non-therapeutic use of antimicrobials
Antimicrobial use in cattle is unavoidable for the treat-
ment of infections for which vaccines, bacterins, or alter-
nate therapies are not available. A prevalent, controversial
practice involves antimicrobials used in non-therapeutic
applications. Judicious antimicrobial use typically requires
that diseased cattle are treated individually to maximize
therapeutic efficacy and reduce the spread of AMR, but
entire herds are often dosed with in-feed antimicrobials.
This is the typical administration route for practices such
as (I) prophylaxis, (II) metaphylaxis, and (III) growth
Fig. 1 Major beef-producing countries and antimicrobial consumption. a Beef and veal production in select countries (t). Data from: ‘Livestock
and Poultry: World Markets and Trade’. USDA. Foreign Agricultural Service [6]. b Antimicrobial sales, excluding ionophore sales, in reporting countries
(t active substance). Data complied from multiple sources: [19–23] c Sales of antimicrobials authorised only for food‐producing animals, by species
(t active substance) [22, 23]. d Weighted animal population (in PCU) [20, 21, 23]. e Proportion of sales of total antibiotic products by antimicrobial class
(t active ingredient) [19–23]
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promotion. These practices are described by inconsistent
and often agenda-driven terminology. For example,
prophylaxis and metaphylaxis are considered therapeutic
uses by the American Veterinary Medical Association and
the US Food and Drug Administration (FDA) [8, 9], but
others consider such practices ‘sub-therapeutic’, ‘non-
therapeutic’, or ‘production usage’. More recently, the
FDA uses ‘production purposes’ to refer to antimicrobial
usage with the intent of growth and feed efficiency en-
hancement [10]. Prophylaxis is action taken to prevent
disease and involves the administration of antimicrobials
to an individual that is perceived to be at risk of develop-
ing disease. Metaphylaxis refers to the treatment of a
larger cohort or entire herd to provide: (I) therapy to
infected animals, and (II) prophylaxis to uninfected or
potentially susceptible animals. Metaphylaxis is often
applied to herds receiving new animals. Growth promo-
tion refers to the use of antimicrobial growth promoters
(AGPs) for extended duration to improve feed efficiency
(the ratio of feed consumed vs. animal weight gain).
‘Sub-therapeutic’ typically refers to low-dose concentrations
of antimicrobials in feeds over an extended duration. The
FDA Centre for Veterinary Medicine defines sub-therapeutic
as amounts <200 g per ton (US) of feed for 12 wk [11].
Complexity of production usage of antimicrobials
Although prophylaxis/metaphylaxis may be a more
judicious use of antimicrobials than growth promotion,
growth promotion is often a benefit of either treatment.
For example, antimicrobial treatment and prevention of
cattle liver abscesses simultaneously provides prophylac-
tic/metaphylactic therapy and growth promotion. Liver
abscesses occur frequently in cattle, and are common in
feedlots, where high-energy grain-based diets can cause
acidosis, leading to ruminal lesions that predispose cattle
to hepatic disease caused by invasive bacteria [12]. Cattle
with liver abscesses have reduced production efficiency
(reduced feed intake and weight gain) [12]. Thus, feedlot
cattle receiving antimicrobials for liver abscess control
can also indirectly exhibit growth promotion as a result
of disease prevention. Some antimicrobials are approved
for both growth promotion and therapeutic applications
[13, 14]. Some countries, particularly in the EU, have
banned the use of AGPs in beef and other meat produc-
tion industries (the EU ban was implemented in 2006
[15]). In 2012, the US introduced a voluntary ‘ban’ on
AGPs, and a similar program is expected in Canada [16].
While such policies are laudable, their effectiveness is
questionable. For example, the volume of agricultural
antimicrobials used within the EU has not decreased,
and the EU ban may also have resulted in compensatory
increases in the usage of antimicrobials with even greater
relevance to human health [17]. Regardless, bacterial
resistance acquired in response to any antimicrobial usage
could compromise future efficacy, especially in the
case of AMR genes that are genetically linked in
clusters, as is often the case in multi-drug resistant
(MDR) organisms.
Global veterinary antimicrobial usage
Antimicrobial usage data is scarce: most countries do
not survey or collect usage data, and cattle producers
and pharmaceutical companies have little incentive to
report such information. Where usage data exists, typic-
ally in high-income countries, it takes the form of vol-
ume sales data rather than actual usage. The caveat of
antimicrobial sales and distribution data is that it does
not accurately indicate how or if antimicrobials were
used. In a global analysis of antimicrobial usage, Van
Boeckel et al. [18] estimated the worldwide consumption
of antimicrobials in food animal production at ≥57,000 t
(1 t = 1,000 kg) and projected a 67% increase in total
usage by 2030 to ≥95,000 t. Total food-animal anti-
microbial sales in the US was reported to be approxi-
mately 9,475 t (2014) [19], 8,122 t in the EU (2013) [20],
1,127 t in Canada (2012) [21], 644 t in Australia (2010)
[22], and 429 t in the United Kingdom (UK) (2014) [23]
(Fig. 1b; excludes ionophores sales). Based on these sales
data, and estimations of food animal populations, Van
Boeckel et al. projected that the top countries consum-
ing antimicrobials in livestock production are China, the
US, India, Brazil and Germany, with China accounting
for 23% of global consumption [18].
Data for antimicrobial usage by animal type is not
routinely available, such that the proportion and type of
antimicrobials sold exclusively for use in cattle is largely
unknown or estimated. Some information can be
gleaned from country data where specific antimicrobial
formulations with indicated routes of administration
(e.g. in-feed, injection etc.) are provided for specific live-
stock (Fig. 1c). However, this data is largely unreliable
because (I) most antimicrobials are approved for use in
multiple food-animal species, (II) off-label non-intended
usage of antimicrobials is a common practice worldwide,
and (III) the antimicrobial may not have actually been
administered to the animal. Data on therapeutic vs. non-
therapeutic use is not collected, and difficult to estimate.
Without reliable antimicrobial usage data to link to
AMR, it is challenging to create scientific policies to
optimize veterinary antimicrobials. Thus, judicious use
policies in some countries are the subject of debate, with
critics decrying heavy-handed bans and regulations, and
proponents criticizing ineffective and optional compli-
ance schemes.
One method to improve antimicrobial usage estimate
by species is to take into account (I) the size of the animal
population (demographics), and (II) the average theoret-
ical weight of the animal species at time of treatment
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(physiology). This is the population correction unit (PCU),
and is used in the UK Veterinary Medicines Directorate
UK-VARSS report [23], the EU European Medicines
Agency ESVAC report [20], and the Public Health Agency
of Canada’s CIPARS report [21]. Briefly, 1 PCU = 1 kg of
livestock, such that the amount of antimicrobials sold can
be normalized by species weight, allowing for a compara-
tive indication of overall usage between species (Fig. 1d).
Van Boeckel et al. used PCU values to estimate global
consumption of antimicrobials per kg of animal produced
at 45 mg/PCU (= mg/kg) for cattle, 148 mg/PCU for
chickens, and 172 mg/PCU for pigs [18]. This trend is
consistent with UK-VARSS data, in which cattle
consumed 8 mg / PCU of antimicrobials compared to
172 mg / PCU for swine and poultry [24]. This ap-
proach gives an appreciation for the overall use of
antimicrobials within a livestock species, but does not
indicate usage within the various segments of the pro-
duction system. These are limitations of using antimicro-
bial sales and distribution data as a proxy for actual
usage data [23].
In some countries, the majority of antimicrobials man-
ufactured or sold are used in food animals rather than in
human medicine (e.g. US: ~10,670 t active ingredient for
food animals (2014) vs. ~3,290 t for humans (2012) [19,
25]; EU: ~7,982 t active ingredient for food animals vs.
~3,399 t (2012) [26] (food animal values exclude iono-
phores and other non-medically important antimicro-
bials)). However, direct human-animal antimicrobial use
comparisons are limited by differences in estimation and
measurement methodology (e.g. antimicrobials sold vs.
prescribed), differences in animal physiology and anti-
microbial use practices, and are further complicated by
the inclusion/exclusion of antimicrobials irrelevant to
human medicine (e.g. ionophores). Thus, food animal vs.
human antimicrobial consumption comparisons must be
interpreted with caution. Since food animals outnum-
ber/outweigh the human population, volume usage is
less surprising than the concurrent use of antimicrobials
essential for human medicine. The FDA reports that
medically important antimicrobials accounted for 62% of
sales of all antimicrobials approved for use in food-
producing animals [19], with 74% of clinically relevant
antimicrobials administered in-feed [19]. Of the 38% of
antimicrobials sold that were not medically important,
80% were ionophores (e.g. monensin). Ionophores are not
used in human medicine, have no human counterpart, and
do not appear to promote AMR. However, ionophores are
important for animal welfare, and are administered for
production and therapeutic indications for the treatment/
prevention of coccidiosis, a disease associated with
Eimeria spp. infestations [24]. In the EU, ionophores are
defined as anticoccidials/coccidiostats, and are not re-
ported as antimicrobials [20, 23]. Besides the ionophores
and another class of AGPs called flavophospholipols, most
veterinary antimicrobials are identical or structurally simi-
lar to antimicrobials used in human medicine. Stringent
EU policies regulate the use of in-feed antimicrobials, and
penicillins sales are proportionally high-from a low of
11.9% in France to as high as 61.3% in Sweden of all vet-
erinary antimicrobials sold [20]. Sweden was the first
country to ban AGPs in 1986 [17], a policy that likely con-
tributed to high therapeutic use of penicillins. Resistance
to an agricultural antimicrobial may confer resistance to
the human drug, many of which are considered to be es-
sential medicines by the World Health Organization
(WHO) [27]. Significant veterinary antimicrobials gener-
ally include tetracyclines, penicillin (penam) and other β-
lactams, macrolides, sulfonamides, and aminoglycosides
(Fig. 1e). Other antimicrobials represent a miniscule
fraction of veterinary antimicrobials sold and distributed
(each <2%), but they are not unimportant. Thus, cephalo-
sporins, lincosamides, phenicols, and fluoroquinolones
(among others) include some of the most effective anti-
microbials in veterinary and clinical medicine.
Antimicrobial resistance in bovine pathogens
Much focus on AMR in food animals concerns the haz-
ards for human health, but AMR is also a veterinary
problem. Knowledge about resistance in exclusively
bovine pathogens is also exceptionally poor compared to
that of bovine zoonotic enteric pathogens, such as
Campylobacter, Salmonella, E. coli and Enterococcus spp.
These species are typically used as ‘indicators’ of AMR
in production animals as they (I) are of importance in
human disease, (II) are relatively easy to culture, (III)
can be isolated from healthy animals, and (IV) have
established AMR minimum inhibitory concentration
(MIC) breakpoints (for human infections). To reiterate,
for several of the bacterial species discussed below, the
designation of “resistant” or “sensitive” is often author-
determined because clear criteria have not been estab-
lished by relevant standardization bodies, such as the
Clinical Laboratory Standards Institute (CLSI), and the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST). Surveillance programs monitoring
AMR in beef production are typically constrained to
human enteropathogens and sentinel AMR indicator
species, but independent research from many countries
gives rough estimates of AMR in cattle pathogens. Several
recent studies have found strong correlations between the
level of use of specific antimicrobials and the level of
resistance observed [28, 29].
Scientific literature pertaining to AMR in pathogens of
significance to beef production was reviewed, and the
median percent resistance of 16 different pathogens to
antimicrobials was collected from 58 scientific reports
([30–88]; 2000-present), shown in Fig. 2 (see Methods
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for details). Reports were selected if they contained an
antibiogram of isolates without prior antimicrobial selec-
tion, and in most cases, if the isolates were obtained from
diseased animals. In general, differing levels of tetracycline
resistance were present in most cattle-associated bacteria.
Macrolide resistance was often reported in BRD patho-
gens, and in liver abscess pathogens. For almost every spe-
cies there was a report of resistance to at least one
antimicrobial from each major antimicrobial class. A cav-
eat of many of the studies selected is that MIC resistance/
sensitivity breakpoint criteria have not been defined for
many cattle pathogens, as well as some antimicrobials
(e.g. streptomycin). Complicating a general view of resist-
ance across multiple species are the following caveats: (I)
some studies do not test the same antimicrobials as
others, (II) for some species, reports are very scarce, (III)
some studies test relatively few isolates for resistance, (IV)
in some cases, designation of resistance is defined by the
author and not via standardized interpretive criteria, and
(V) the median value of percent of resistance is biased
towards values for which there are fewer comparative data
points. Thus, the data presented in Fig. 2 should be viewed
with caution.
Antimicrobial resistance in bovine respiratory pathogens
Bovine Respiratory Disease (BRD) is the most frequent
and economically important of the primary cattle diseases
[89]. Approximately 15% of cattle in North America are
treated for BRD, which accounts for ~70% of cattle mor-
bidity, and ~40% of all mortality in feedlots [90]. BRD
control is thus a major target of antimicrobial usage [90,
91], and possibly an important source of AMR pathogens.
BRD involves a complex of etiological agents including
Mannheimia haemolytica, the predominant agent [92],
Pasteurella multocida, and Histophilus somni [92, 93]. H.
somni occurs sporadically, and can cause fatal septicemia
in cattle. Mycoplasma bovis is also frequently associated
with BRD [94]. These ubiquitous pathogens are often de-
scribed as commensals because colonization is asymptom-
atic in most healthy animals. As opportunistic pathogens,
respiratory disease may develop with detrimental changes
to the immune status of the host animal as a result of
stress (e.g. transportation, weaning) or viral infections (e.g.
Bovine Herpes Virus-1, Bovine Respiratory Syncytial
Virus) [89]. Typing of M. haemolytica isolates obtained
from fatal pneumonia cases in calves show substantial
diversity [95], suggesting that outbreaks of BRD are not due
Fig. 2 Most frequently reported antimicrobial resistance in pathogens from diseased bovines. Diameter of circle indicates the percent resistance
of phenotypic resistance to antimicrobials, by class. The percent resistance was determined via the median of percent values obtained from
journal articles (references [30–88]) that reported the percentage of resistance among isolates collected from diseased animals or from passive
surveillance (as indicated). Notes: a,bincludes resistance data from healthy animals; c,d,eincludes data from healthy animals, sub-clinical, and clinical
mastitis; eincludes isolates from feces. Data compiled from multiple sources
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to the herd-wide transmission of a single virulent strain,
but originate from formerly commensal strains [95, 96]. In
North America and many countries, macrolides are often
given as BRD metaphylaxis to asymptomatic animals in the
presence of diseased animals. Individual cattle symptomatic
for BRD may also be treated with a wide range of antimi-
crobials, with the fluoroquinolone marbofloxacin used in
this manner [97]. Clinical symptoms may only become ap-
parent after pulmonary damage has occurred. Conse-
quently, metaphylactic control of BRD often improves the
welfare of cattle as well as financial returns through cost
savings achieved by reduction in morbidity and mortality
[98].
In calves experimentally infected with M. haemolytica
(4 × 107 CFU), Lhermie et al. [97] demonstrated that
low-dose (2 mg/kg) marbofloxacin 12 h after inoculation
eliminated this pathogen from all calves, but at 45 h
post-inoculation a high-dose (10 mg/kg) failed to do so.
Since M. haemolytica persisted after this high-dose, a
higher risk for AMR development may have been cre-
ated by a practice thought to be more judicious than
mass medication [97]. Thus, although metaphylactic
approaches may expose more bacteria to antimicrobial
selection, they may also reduce pathology, and eliminate
pathogens more effectively than single-dose therapeutic
approaches. In another study, continuous sub-therapeutic
administration of the macrolide tylosin (Tylan, Elanco;
11 mg/kg in-feed) had no effect in reducing carriage of M.
haemolytica in beef cattle, compared to substantial reduc-
tions after therapy with a single subcutaneous injection of
tilmicosin (Micotil, Elanco; 10 mg/kg) or tulathromycin
(Draxxin, Pfizer; 2.5 mg/kg) [99]. Antimicrobial usage in
single animals has been shown to increase the risk of iso-
lating both susceptible and MDR M. haemolytica from
pen mates, highlighting the importance of bacterial trans-
mission in the dissemination of AMR [100]. Furthermore,
Klima et al. [101] found that MDR occurred more fre-
quently in diseased than healthy cattle (37% vs. 2%) in M.
haemolytica collected from healthy cattle vs. cattle with
clinical BRD. In that study, tetracycline resistance
(18%) was the most prevalent resistance phenotype [101].
Resistant M. haemolytica and P. multocida can also be re-
covered from diseased antimicrobial non-treated cattle.
Via the pan-European VetPath susceptibility monitoring
program, de Jong et al. [45] analyzed isolates collected
between 2002 and 2006 from diseased cattle with no
antimicrobial exposure for at least 15 d prior to sampling,
and found that 14.6% of M. haemolytica (231 total iso-
lates) were resistant to tetracycline, and 5.7, 3.5 and 0.4%
of P. multocida (138 total isolates) were resistant to tetra-
cycline, spectinomycin, and florfenicol, respectively [45].
MDR has also been reported in BRD agents. Lubbers
et al. [102] evaluated records from 2009 to 2011 from
the Kansas State Diagnostic Laboratory for co-resistance
in M. haemolytica to 6 antimicrobial classes including
ceftiofur, danofloxacin and enrofloxacin, florfenicol, oxy-
tetracycline, spectinomycin, tilmicosin and tulathromy-
cin. They found that in 2009, ~5% of isolates were
resistant to 5 or more antimicrobials as compared to
~35% in 2011 [102]. M. haemolytica isolates resistant to
oxytetracycline were 3.5-fold more likely to be resistant
to 1 or more antimicrobials, compared to non-
oxytetracycline-resistant isolates [102]. MDR has been
detected in P. multocida and H. somni. Klima et al. [92]
isolated M. haemolytica, P. multocida and H. somni
from BRD mortalities, and determined that 72% of M.
haemolytica and 50% of P. multocida isolates exhibited
AMR. Surprisingly, 30% of M. haemolytica and 12.5%
of P. multocida were resistant to >7 antimicrobial clas-
ses, including aminoglycosides, penicillins, fluoroquino-
lones, lincosamides, macrolides, pleuromutilins, and
tetracyclines [92]. The MDR isolates originated from
feedlots in Texas or Nebraska. MDR was found in mul-
tiple M. haemolytica populations, suggesting that a
clonal population was not responsible for this observa-
tion [92]. MDR was due to a tandem array of AMR
genes concentrated within an Integrative and Conjugable
Element (ICE), a mobile genetic element (MGE) [92].
These elements constitute a diverse group of MGEs
found in both Gram-positive and -negative bacteria, and
are notable for encoding the conjugation machinery re-
quired for mobilisation of ICE to other bacteria, where
they often integrate into multi-copy genes such as
tRNAs and rRNAs. ICEs also frequently encode virulence
factors, heavy metal transporters, and toxin-antitoxin sys-
tems, thought to ensure the stability of chromosomally-
inserted ICE within cells.
A putative ICE, designated ICEMh1, was recently de-
tected in M. haemolytica strain 42548 by Eidam et al.
that carried resistance to aminoglycosides (aphA-1, strA,
strB genes), tetracyclines (tet(H) gene), and sulfonamides
(sul2 gene) [103, 104]. ICEMh1 has a size of 92 ,345 bp,
harbors ~107 genes, and shares a high degree of similar-
ity with ICEPmu1, an ~82 kb element identified in P.
multocida that encodes ~88 genes [104]. The structure
of ICEPmu1 is depicted in Fig. 3a. ICEPmu1 integrates
into a chromosomal copy of tRNALeu [105]. Eleven re-
sistance genes are encoded within two gene clusters,
conferring resistance to tetracyclines (tetR-tet(H) genes),
streptomycin (strA and strB), streptomycin/spectino-
mycin (aadA25), gentamicin (aadB), kanamycin/neomy-
cin (aphA1), phenicols (floR), sulfonamides (sul2),
macrolides/lincosamides (erm(42) gene) or tilmicosin/
tulathromycin (msr(E)-mph(E) genes) [92, 105].
ICEPmu1 was shown to conjugatively transfer in vivo
into recipient P. multocida, M. haemolytica and E. coli
at frequencies of 1.4 × 10−4, 1.0 × 10−5 and 2.9 × 10−6 re-
spectively [105]. E. coli transconjugants demonstrated up
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to 64-fold higher MIC values for florfenicol, suggesting
better functional activity of FloR in E. coli [105]. A β-
lactam oxacillinase (blaOXA-2) was also present, and con-
ferred greater ampicillin resistance in E. coli harboring
ICEPmu1 [105]. As many of the ICEPmu1 resistance
genes may not be indigenous to Pasteurellaceae, acquisi-
tion of AMR determinants from Enterobacteriaceae is
likely [105]. ICEPmu1 and ICEMh1 were isolated from
feedlot BRD cases in Nebraska in 2005 and Pennsylvania
in 2007, respectively [104, 105]. There is currently little
information on the prevalence of these or similar ICE el-
ements in herds, but the presence of AMR-ICEs in BRD
agents represents a critical risk for the efficacy of future
antimicrobial therapy. Simultaneous and rapid acquisi-
tion of multiple resistance genes via a single HGT event
could severely limit therapeutic options.
Besides HGT via MGEs, AMR determinants arise
spontaneously via mutation. In some isolates of M. hae-
molytica and P. multocida, high-level (MIC ≥ 64 mg/L)
macrolide resistance has been attributed to mutations in
the multicopy 23S rRNA genes (e.g. M. haemolytica
A2058G; P. multocida A2059G) [106]. Resistance to
macrolides, lincosamides and other ribosome-targeting
antibiotics has been shown to be conferred by mono-
methylation of the M. haemolytica and P. multocida 23S
rRNAs at position A2058 [107]. Methylation is catalyzed
by a novel monomethyltransferase, designated erm(42),
which appears to have been disseminated among the
Pasterellaceae [107]. Plasmid borne transfer of AMR
genes may also be significant among BRD bacteria. In
the first report of a floR florfenicol resistance gene in M.
haemolytica, Katsuda et al. [108] identified pMH1405, a
7.7 kb florfenicol resistance plasmid, which appears to
be remarkably similar to plasmids from P. multocida
(pCCK381; 10.8 kb) and Dichelobacter nodosus (pDN1;
5.1 kb). Collectively, these findings reveal the importance
and diversity of AMR and HGT mechanisms in BRD
pathogens.
Antimicrobial resistance in liver abscess pathogens
Liver abscesses in beef cattle result from aggressive
grain-feeding, and represent an economic liability. Liver
abscess incidence in North American feedlot cattle
ranges from 12 to 32% [12]. Fusobacterium necro-
phorum, an anaerobic rumen bacterium, is the major
etiological agent isolated from condemned livers,
followed closely by Trueperella pyogenes [12]. Hepatic
disease is detected after slaughter since cattle with ab-
scesses are usually asymptomatic. Liver perforation that
leads to systemic infection is rare. In-feed antimicrobials,
such as the FDA-approved tylosin, chlortetracycline,
oxytetracycline, bacitracin, and the streptogramin, virgi-
niamycin, are approved for liver abscess prevention in
many countries. In a study of ~7,000 feedlot cattle, tylo-
sin reduced the incidence of liver abscesses by up to
70%, and increased weight gain by 2.3% [12, 109]. Al-
though a common rumen inhabitant, F. necrophorum is
an opportunistic pathogen also associated with calf diph-
theria and foot rot [110]. In a 2-year comparison of flora
isolated from liver abscesses in cattle fed with or without
tylosin, Nagaraja et al. [111] found that the incidence of
T. pyogenes in mixed culture with F. necrophorum was
higher in abscesses from tylosin-fed cattle (53% vs. 10%
in the non-tylosin fed cattle). In contrast, the incidence
of F. necrophorum was higher in cattle that were not fed
tylosin (61%), as compared to those that were (33%).
No differences in tylosin susceptibility between isolates
from antimicrobial-free or tylosin-exposed cattle were
Fig. 3 Antimicrobial resistance determinants in mobile genetic elements. a Organization of the Integrative and Conjugative Element (ICE)
ICEPmu1 found in the BRD agent Pasteurella multocida [179]. Resistance gene clusters 1 and 2 are shown expanded in grey. b Circular distribution
of antimicrobial resistance genes by class, and abundance in total annotated antimicrobial genes found six plasmid metagenomes from the
influent and sludge from two wastewater treatment plants (modified and reproduced with permission from [192])
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identified [111]. AMR in Fusobacterium spp. isolated
from humans is also relatively rare [112, 113], suggesting
that AMR in this genera is yet to present a major risk to
beef production or human medicine. AMR in bovine T.
pyogenes is of greater concern, due to the versatility of
the bacterium as a cause of liver, skin, joint, and visceral
abscesses, and roles in mastitis and abortion [114]. Tylosin
resistance has been documented and linked to the pres-
ence of erm(X) or an erm(B) gene similar to that found on
the Enterococcus faecalis MDR plasmid pRE25 [115, 116].
This suggests AMR transfer occurs between these human
and cattle pathogens. Jost et al. [116] examined 48T. pyo-
genes isolates, of which 27 were derived from cattle, and
identified erm(X) as the most prevalent tylosin resistance
determinant. An erm(X) tylosin and tetracycline tet(33) re-
sistance plasmid, pAP2, was also identified [116]. Other
studies have found high prevalence of tetracycline and sul-
fonamide resistance, and suggest that AMR in T. pyogenes
may of greater significance in bovine mastitis as compared
to liver abscesses [117, 118].
Antimicrobial resistance in keratoconjunctivitis pathogens
Infectious bovine keratoconjunctivitis is a painful ocular
disease caused primarily by non-self-limiting infections
with Moraxella bovis and bovoculi. The disease is com-
mon worldwide in cattle, transmitted by flies, and if un-
treated, may result in ulceration and cornea rupture. In
the US, only oxytetracycline and tulathromyin are ap-
proved for the treatment of bovine keratoconjunctivitis,
although penicillin may be used in other countries. In a
study of 32 Moraxella spp. isolated from cattle and
sheep, Maboni et al. [119] found that 40% of isolates
were penicillin-resistant and 20% were tetracycline-
resistant, but most were susceptible to other antimicro-
bials. Dickey et al. [120] published the genome sequence
for an AMR isolate of Moraxella bovoculi, Mb58069. It
was found to be resistant to florfenicol, oxytetracycline,
sulfonamides, and displayed intermediate resistance to
macrolides. Ten AMR determinants were co-located on
a >27 kb genomic island [120]. The biofilm-forming cap-
abilities of Moraxella bovis may also enhance antimicro-
bial resistance. Prieto et al. [121] found that Moraxella
bovis readily forms biofilms, increasing resistance to
ampicillin, chloramphenicol, gentamicin, and oxtetracy-
cline by 256-, 1,024-, 512-, and 1,024-fold as compared
to when this bacterium grows planktonically [122] Thus,
antimicrobial susceptibility via standard disk diffusion
and microtiter MIC determinations failed to reflect the
true level of resistance of this isolate.
Antimicrobial resistance in notifiable/reportable bovine
bacterial pathogens
Many countries maintain registries of notifiable diseases
associated with zoonotic, unvaccinable, highly infectious,
economy-damaging, or largely untreatable pathogens.
For cattle, notifiable diseases include (I) abortive agents:
Brucella abortus (Brucellosis), Coxiella burnetti (Q
fever), and Leptospira spp. (Leptospirosus); (II) bovine
pneumonia agents: Mycoplasma mycoides subsp.
mycoides small colony type (Contagious bovine pleuro-
pneumonia), and Mycobacterium bovis (Bovine tubercu-
losis); and (III) enteritis agents: Mycobacterium avium
subsp. paratuberculosis (Johne’s disease), and Bacillus
anthracis (Anthrax) [123]. Although it might be as-
sumed that AMR would be a major issue in these patho-
gens, for the most part AMR has not been studied in
these pathogens or is rare. Besides the rarity of cases,
other reasons for this include: (I) the notifiable pathogen
is already intrinsically resistant to many antimicrobials
(e.g. Mycobacterium spp.); (II) the pathogen resides in an
antimicrobial-exclusive intracellular niche that renders
antimicrobial therapy impractical (e.g. Brucella abortus
and Coxiella burnetti); or (III) a secreted toxin causes
pathology (e.g. Bacillus anthracis). Control of outbreaks
of these diseases rarely involves antimicrobial therapy
and relies on animal segregation, herd control, or de-
population [13].
AMR susceptibility tests of human clinical isolates of
Mycobacterium bovis have been performed because of
the role of M. bovis in human tuberculosis (TB). Al-
though it can infect many species, the main reservoir of
M. bovis is cattle, and transmission to humans is primar-
ily via contact with infected animals and drinking
unpasteurized milk [124]. In clinical isolates of M. tuber-
culosis and M. bovis collected over 15 yr, Bobadilla-del
Valle et al. [125] found that 16.6% of isolates from human
TB cases were M. bovis. Susceptibility testing to first-line
anti-TB drugs revealed that 10.9% of M. bovis were
streptomycin-resistant, and 7.6% were MDR (isoniazid-
and rifampin-resistant). The aminoglycoside streptomycin
is approved for use in cattle against aerobic Gram-
negatives such as enteritis-causing E. coli and Salmonella
spp. [14]. Bovine-human transmission of AMR M. bovis
appears to be rare in developed countries, but may occur
more frequently in developing countries [124, 126].
Antmicrobial resistance in zoonotic human
enteropathogens
Antimicrobial resistance in bovine-origin Escherichia coli
Cattle are E. coli reservoirs, with most strains harmless
commensals. Some E. coli, particularly invasive and
enterohemorrhagic E. coli (EHEC) cause septicemia in
neonatal calves, but are primarily pathogenic to humans.
E. coli strains from bovines and other food production
animals serve as indicators of AMR prevalence in
Gram-negative bacterial populations, thus sentinel ‘generic’
E. coli help establish and track the persistence of AMR
genes in environments affected by beef production and
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other human activities. For example, in a recent survey of
AMR in E. coli from Nebraska cattle feedlot runoff catch-
ment ponds and the effluent of municipal wastewater
treatment plants, Agga et al. [127] found that the diversity
of AMR genes in human-associated samples was greater
than from environments impacted by cattle. Interestingly,
E. coli resistant to 3rd generation cephalosporins and tri-
methoprim/sulfamethoxazole were found at equivalent
high-frequency (>70% of E. coli isolates) in both livestock
and municipal wastewater environments [127].
Extended-spectrum β-lactamases (ESBLs) that inacti-
vate newer cephalosporins are a major focus of sentinel
E. coli susceptibility testing. Cottell et al. [128] evaluated
E. coli originating from 88 steers that were treated with
ceftiofur and/or chlortetracycline in an experimental US
feedlot. The ESBL blaCTX-M-32, was detected in
cefoxatime-resistant E. coli in 29 animals, and was found
to be present on a self-transmissible IncN-family plas-
mid (reviewed in [129]). In Germany, blaCTX-M-1 was the
predominant ESBL in E. coli, found on 87% of assessed
farms [130]. In a Swiss study of the wider food process-
ing chain, Geser et al. [131] screened for ESBL in fecal
samples collected at slaughter as well as in raw milk,
and minced beef. They found that of 124 bovine fecal
samples 13.7% hosted ESBL-producing bacteria, 98% of
which were E. coli. Despite enrichment for ESBL-
producing organisms, ESBL were not detected in raw
milk or minced beef samples. The ESBLs detected in the
study included blaCTX-M-1, blaTEM-1blaCTX-M-14, blaCTX-
M-117, and blaCTX-M-15. Many of the ESBL-positive iso-
lates were frequently co-resistant to tetracycline (76%),
trimethoprim/sulfamethoxazole (76%), nalidixic acid
(47%), at least one aminoglycoside (76%), chloram-
phenicol (65%) and ciprofloxacin (41%). The authors
suggested that slaughter hygiene prevented the transmis-
sion of ESBLs into the food chain [131]. Similarly, the
prevalence of AMR E. coli O157:H7 was investigated in
510 fecal, hide, carcass, and raw meat samples from 4
beef slaughterhouses in China. STEC was detected in
1.4% of fecal and hide sample, but not in pre- and post-
evisceration carcasses, nor in raw meat samples, with all
isolates sensitive to 16 relevant antimicrobials [132].
During slaughter, cattle hides are major contributors to
carcass contamination [133, 134]. In another study
tracking E. coli resistant to 3rd-generation cephalospo-
rins or trimethoprim/sulfamethoxazole, Schmidt et al.
[135] determined the prevalence of generic and AMR E.
coli at various sites along the beef processing continuum.
The prevalence of cephalosporin-resistant and trimetho-
prim/sulfamethoxazole-resistant E. coli in fecal samples
at processing was 75 and 95%, respectively. Prevalence
in pre-evisceration carcasses was 3 and 33%, and resist-
ant isolates were only found in 0.5% of final carcasses,
and no isolates were associated with the final striploin
product. All cephalosporin-resistant E. coli isolated were
resistant to ampicillin, ceftiofur, and ceftriaxone, and
64% of isolates harbored blaCMY, conferring additional
resistance to clavulanate/amoxicillin and cefoxitin [135].
These reports suggest that hygienic practices in beef
processing are effective against AMR bacteria.
Antimicrobial resistance in bovine-origin Salmonella
Non-typhoidal Salmonella spp. (often Salmonella enter-
ica serotype Typhimurium or Enteritidis) are frequent
laboratory-confirmed infectious agents of gastroenteritis.
Although the enteritis is usually self-limiting, invasive S.
enterica spp. infections often require antimicrobial ther-
apy. Cattle are infected/colonized by many Salmonella
species, and ground beef is a vehicle of Salmonella trans-
mission, implicated in 45% of outbreaks linked to beef
[136]. In cattle, susceptible adults develop enteritis, and
calves may also develop septicemia. S. enterica serotypes
Dublin and Newport are associated with bovine salmon-
ellosis, and adult cattle may carry and shed Salmonella
asymptomatically for many years. In humans, serotype
Dublin has the highest proportion of invasive infections
resulting in hospitalization and mortality [137]. Due to
the frequency of infections, the development of AMR in
Salmonella is a risk to human health. In North America,
MDR Salmonella are on average resistant to 7 antimi-
crobials [138]. In the US, Salmonella (and other entero-
pathogens) are collected from humans, animals, and
retail meat for the National Antimicrobial Resistance
Monitoring System (NARMS) [137]. In 2013, Salmonella
was isolated from 7.9% of beef cattle, and in 0.9% of
ground beef samples [137]. MDR (>3 antimicrobials)
was found in 20% of all ground beef serotype Dublin
isolates, many of which were resistant to ampicillin,
chloramphenicol, streptomycin, sulfonamides, and tetra-
cycline [137]. Worse still, the prevalence of ceftriaxone
resistance (3rd generation cephalosporin) in bovine-
origin serotype Dublin increased from 0 to 86% between
1996 and 2013 [137]. As this is a major risk to human
health, adoption and adherence to good practices during
beef processing and proper cooking are critical to pre-
vent transmission [136, 139, 140].
Antimicrobial resistance in bovine-origin Campylobacter
Campylobacter is the most frequent cause of human
bacterial gastroenteritis in the developed world, with
Campylobacter jejuni responsible for >90% of Campylo-
bacter infections [141]. Mostly a self-limiting infection
in humans, severe cases of campylobacteriosis are
treated with drugs such as erythromycin or ciprofloxa-
cin. Campylobacter are frequent colonizers of chickens,
but cattle are an important reservoir, and can carry high
numbers of Campylobacter asymptomatically [142].
Susceptible cattle can suffer from enteritis, and
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Campylobacter fetus subsp. fetus and subsp. venerealis
can cause venereal bovine genital campylobacteriosis,
leading to infertility and abortion [13, 142]. In the
NARMS report, Campylobacter was isolated from 42%
of beef cattle, with 14% of isolates resistant to ciproflox-
acin [137]. In a Japanese study of beef cattle, C. jejuni
was isolated from 36% of cattle on 88% of the farms
surveyed: ~40% of C. jejuni isolates were enrofloxacin-
and nalidixic acid-resistant, but none were
erythromycin-resistant [143]. In a Swiss study of 97
Campylobacter isolates obtained from a beef processing
plant, Jonas et al. [144] found that 31% were
fluoroquinolone-resistant and ~1% were erythromycin-
resistant. Wieczorek et al. [145] examined Campylobac-
ter abattoir prevalence on 812 bovine hides and corre-
sponding carcasses, and found Campylobacter on 25.6%
of hides, and 2.7% of carcasses. The isolates obtained
were equally resistant to nalidixic acid and ciprofloxacin
(38.3%), streptomycin (24.3%), tetracycline (20.9%),
erythromycin (4.3%), and gentamicin (2.6%) [145].
Antimicrobial resistance in bovine-origin Enterococcus
Enterococcus spp. are ubiquitous Firmicutes in the
healthy intestinal microbiota of both humans and cattle,
and indicate fecal contamination. Most Enterococcus
spp. are not foodborne pathogens, nor are they bovine
pathogens [13]. Despite this, isolates of Enterococcus fae-
calis and faecium may cause life-threatening human in-
fections, such as UTIs and meningitis. Control of
enterococci infections is complicated by high-level MDR
[146]. Enterococci are referred to as ‘drug-resistance
gene traffickers’ due to their omnipresence, robustness,
and capability of transferring AMR to other species and
pathogens [147, 148]. E. faecalis transferred gentamicin
resistance plasmids to transplanted human flora in a
BALB/c mouse model [149]. The US NARMS report in-
dicates that Enterococcus were recovered from ~90% of
cattle, and ~80% of retail ground beef tested. The inci-
dence of MDR (>3 antimicrobials) in both E. faecium
and faecalis was lower in cecal isolates from beef cattle
(19 and 14%, respectively) than in cecal samples from
chickens (67 and 46%, respectively) or turkeys (25 and
58%, respectively) [137]. Other studies of AMR Entero-
coccus typically focus on the emergence of resistance to
vancomycin— an antimicrobial used in the treatment of
MRSA and other Gram-positive infections [122, 150].
Vancomycin or linelozid resistance was not detected in
bovine-origin Enterococcus spp. in the United States or
Canada [137, 151], but ~30% of E. faecium NARMS iso-
lates were found to be quinupristin/dalfopristin-resistant
[137]. Overall, despite the possibility for transmission of
pathogenic strains to humans, Enterococcus spp. in the
beef production environment have been studied mainly
for their presumptive importance as AMR determinant
sentinels/reservoirs.
Antimicrobials and the bovine microbiota
Cattle house a dense (>1010 microbes/ml; rumen fluid
[152]) consortia of microbial species in the distinct
physiological niches of the rumen and lower digestive
tract [153]. Different host compartments functionally se-
lect for, and are shaped by, distinct microbial communi-
ties that are essential for the proper physiology and
development of the host [154, 155]. Cattle are dependent
on rumen microbes for feed digestion, and the micro-
biome collectively degrades complex polysaccharides,
converting plant mass into volatile fatty acids for absorp-
tion by the host animal. Core microbial species in the
rumen include Prevotella, Butyrivibrio, Ruminococcus, as
well as many unclassified organisms [156, 157]. Other
bovine niches harbor unique microbial communities,
such as the nasopharyngeal and vaginal tracts [153, 158,
159]. The microbial community in the jejunum also has
a role in feed digestion, and influences feed efficiency
[160]. The fecal microbiota is dominated by Firmicutes
and Bacteroidetes, but also contains Proteobacteria and
human enteropathogens, which are shed in feces [154,
161, 162]. Collectively, the intestinal microbiota hosts a
portion of the cattle resistome.
Unlike in humans and experimental animal models,
there is currently limited information concerning the ef-
fect of antimicrobials on the bovine microbiota/resis-
tome. However, much work describes the effect of
therapeutic and sub-therapeutic administration of anti-
microbials on the prevalence of specific bacteria in bo-
vines. These studies typically involve antimicrobial
administration to a controlled animal cohort, followed
by culture-dependent collection of an organism-of-
interest for susceptibility testing. These approaches pro-
vide a biased snapshot of microbiome changes. Newer
methods include culture-independent collection of meta-
genomic DNA for detection and quantitation of specific
AMR genes by PCR-based methodology, or for high-
throughput sequencing and functional AMR gene annota-
tion (Table 1). There are currently few studies describing
the effects of antimicrobials on microbial population
diversity in bovines using high-resolution sequencing
methodology.
Effect of antimicrobials on the bovine microbiota
Pereira et al. [163] characterized the gut microbiota
(fecal samples) of pre-weaned dairy calves fed raw milk
spiked with ‘residual’ concentrations of ceftiofur (ceftio-
fur sodium; 0.1 μg/mL), ampicillin (ampicillin sodium;
0.01 μg/mL), penicillin (penicillin G sodium; 0.005 μg/
mL), and oxytetracycline (oxytetracycline hydrochloride;
0.3 μg/mL) using 16S rRNA Illumina MiSeq-based
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sequencing. Exposure resulted in Genus-level differ-
ences, but taxa above the Family level were not altered
[163]. The microbiota of exposed calves was also less di-
verse than treatment-free calves [163]. Similarly, Reti et
al. [162] examined the effects of a sub-therapeutic AGP
on the abundance and composition of microflora in the
small and large intestine of adult beef cattle. The US-
and Canada-approved chlortetracycline/sulfmethazine
AGP (Aureo S-700 G, Alpharma) was administered at
350 mg of each antimicrobial per head per day for 28 d
[14]. Compared to non-treated control cattle, beef cattle
administered the AGP showed no differences in bacterial
abundance or richness/diversity composition (deter-
mined via quantitative PCR and terminal restriction
fragment length polymorphism analyses) [162]. Studies
using advanced 16S rRNA metagenomic sequence-based
and whole metagenome methodologies may be of
greater significance in future work exploring the effect
of antimicrobials on the microbiota.
Effect of therapeutic and sub-therapeutic antimicrobial
usage on AMR gene prevalence
Kanwar et al. [164] recently explored the effects of dif-
ferential treatment strategies on the prevalence of AMR
determinants in the fecal metagenome. In a 26-day field
trial, 176 beef steers were divided into 4 cohorts and
given therapeutic doses of ceftiofur (ceftiofur crystalline-
free acid (CCFA), Excede, Zoetis; 6.6 mg/kg body weight)
and/or chlortetracycline (Aureomycin, Alpharma; 22 mg/
kg body weight). One of the four cohorts included steers
in which only 1 of the animals was administered ceftiofur
and chlortetracycline, while the remaining animals re-
ceived chlortetracycline alone. Via quantitative PCR, the
authors determined gene copies/g of wet feces of blaCMY-2
and blaCTX-M (ceftiofur resistance), tet(A) and tet(B)
(tetracycline resistance), and 16S rRNA genes in fecal
community DNA from the pens of each treated cohort.
Pens where all cattle were treated with ceftiofur had
greater numbers of blaCMY-2 and blaCTX-M ceftiofur resist-
ance determinants than single-animal treatment pens
[164]. Chlortetracycline treatment increased the levels of
blaCMY-2 and blaCTX-M gene copies compared to cattle in
pens that did not receive chlortetracycline. In contrast,
tetracycline AMR gene prevalence decreased in pens
where all cattle received ceftiofur compared to pens where
only one animal received ceftiofur [164]. The authors
discussed these findings in the context of expansion
or suppression of singly- or co-resistant AMR popula-
tions under antimicrobial selection, which served to
highlight the complexity of the effects of antimicro-
bials on the resistome, and the potential for discrep-
ancies between culture- and non-culture-based AMR
quantitation methodologies [164].
Utilizing advanced total community metagenomic se-
quencing, Chambers et al. [165] examined the effect of
ceftiofur treatment on the prevalence of AMR genes in
the bovine fecal microbiome. Holstein cows were
injected subcutaneously with ceftiofur (CCFA, Excede,
Zoetis; 1 mg per 45.4 kg body weight) and fecal samples
were collected prior to and post-treatment. Total DNA
was sequenced on the Illumina HiSeq platform, and
AMR genes were detected using the antibiotic resistance
genes database (ARDB) [166]. The proportion of β-
lactam and MDR sequences were found to be higher in
ceftiofur-treated cows relative to control cows. The β-
lactamase genes cfxA2 and cfxA3 were most abundant,
and have previously been associated with Prevotella—a
common rumen microbe [167]. Ceftiofur also changed
the fecal bacterial community composition, increasing
Bacteroidia and decreasing Actinobacteria. This study
was also notable because metagenomic data was function-
ally assessed with MG-RAST [168], allowing examination
of antimicrobial-induced changes to the metagenome.
Functional ceftiofur-associated shifts included increased
prevalence of genes associated with stress, chemotaxis,
and resistance to toxic compounds [165]. This work and
others like it likely represent the future direction of AMR
surveillance research.
Sub-therapeutic antimicrobial administration is one of
the most controversial beef production practices with
many studies exploring this topic in the context of AMR
development. Alexander et al. [169] investigated effects
of chlortetracycline/sulfamethezine AGPs (Aureu S-700
G, Alpharma; 44 mg/kg each in-feed) on the prevalence
of AMR E. coli in the beef production continuum. With
respect to treated and non-treated cattle, E. coli was col-
lected from live-animal feces, hides, intestinal digesta,
carcasses, and ground beef. Animals fed chlortetracyc-
line/sulfamethezine harbored more tetracycline-resistant
E. coli than non-treated animals (50.9% vs. 12.6%), but
there were no differences in the prevalence or profile of
AMR E. coli between treatments in the hide, carcass or
ground beef samples [169]. To the authors this sug-
gested that AMR E. coli can enter the food chain at
slaughter regardless of AGP administration [169]. Sub-
therapeutic administration of tetracycline/sulfamethazine
also increased the prevalence of tetracycline-resistant or-
ganisms, and increased the frequency of ampicillin-
resistant E. coli, in agreement with similar studies using
the same antimicrobials [170]. Another study found that
sub-therapeutic tylosin treatment (Tylan, Elanco; 11 mg/
kg in-feed) increased the frequency of Enterococcus spp.
harboring erm(B) and/or msrC (a macrolide/streptogra-
min efflux pump gene) [171]. The authors of that study
concluded that the diversity of Enterococcus decreased in
the period between when cattle entered and exited the
feedlot, and that the AMR Enteroccocus were derived
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from strains present in the intestinal microbiota before
tylosin administration [171]. Selection for co-resistance
and MDR is one of the main arguments against AGPs.
Effect of BRD-related antimicrobial usage
Given the importance of antimicrobials in the treatment
of BRD agents, much research examines the effect of
antimicrobial treatment on AMR development in BRD
bacteria. Investigated the effects of therapeutic and sub-
therapeutic macrolide administration on the nasopha-
ryngeal and enteric microbiota, with specific focus on
M. haemolytica and Enterococcus, respectively. Forty
beef steers were injected once with tilmicosin (Micotil,
Elanco; 10 mg/kg) or tulathromycin (Draxxin, Pfizer;
2.5 mg/kg) or fed sub-therapeutic tylosin (Tylan, Elanco;
11 mg/kg in-feed) continuously over 28 d. Therapeutic
tilmicosin and tulathromycin decreased nasopharyngeal
carriage of M. haemolytica: at the beginning of the trial,
60% of the steers tested positive for M. haemolytica, at
7 d post- injection, none of the steers treated with tilmi-
cosin harbored M. haemolytica, and only one steer
treated with tulathromycin was positive for M. haemoly-
tica. Sub-therapeutic tylosin had no effect on nasopha-
ryngeal carriage, and tylosin-exposed M. haemolytica
isolates did not acquire macrolide resistance. In contrast,
a significant proportion of the bystander Enterococcus
acquired erm(B) erythromycin resistance following treat-
ment with either injectable tilmicosin or tulathromycin,
or in-feed tylosin, and were 76-fold more likely to be
erythromycin-resistant than those recovered from non-
antimicrobial-treated steers. Catry et al. [172] correlated
2-year of Belgian farm-standard antimicrobial usage to
the occurrence of AMR in rectum and nasal flora, repre-
sented by E. coli and Pasteurellaceae, respectively. Nar-
row spectrum penicillins were the most frequently
administered parenteral antimicrobials, often in combin-
ation with an aminoglycoside, such as neomycin or dihy-
drostreptomycin [172]. Among rectal E. coli, 20.6% were
resistant to least one antimicrobial. The most frequent
resistance patterns were ampicillin-tetracycline-
streptomycin (15.9%), tetracycline-streptomycin (11.4%),
and ampicillin-streptomycin (9.8%) [172]. Among 206 P.
multocida isolates and 42 M. haemolytica isolates origin-
ating from the nasal cavity, the predominant resistance
found was to the aminoglycoside spectinomycin [172].
The authors confirmed that antimicrobials altered the
prevalence of AMR in the digestive and respiratory tracts
and highlighted that the route of administration affected
resistance outcomes. Individual therapy was linked to in-
creased but transient resistance, whereas in-feed antimi-
crobials were linked to higher levels of MDR [172]. Others
have also suggested that the route of administration affects
overall AMR prevalence [173, 174], but there are also
contradictory reports where no such association exists
[99, 175].
Heavy metal supplementation and AMR
Cattle also receive trace mineral supplements that in-
clude elements with AGP activity. Some heavy metals,
such as zinc, manganese, and copper may be given as
salt-mixes, injected, or administered in slow-release ru-
minal capsules [14]. Copper and zinc promote growth,
potentially via suppression of pathogens and alteration
of microbiota [176, 177]. In other production animals,
zinc and copper can select for AMR [178]. This may be
due in part to MGEs such as ICE, in which AMR deter-
minants are co-localized with heavy-metal resistance
genes. For example, in addition to multiple AMR deter-
minants, ICEPmu1 (Fig. 3a) encodes for a multi-copper
oxidase, which is potentially involved in resistance to
copper and other heavy metals [179]. Thus, heavy metal
exposure can co-select for AMR. Jacob et al. [180] stud-
ied the effect of elevated copper and zinc fed to heifers
receiving high-energy rations by isolating and character-
izing AMR E. coli and Enterococcus from fecal samples.
Resistance to copper and zinc in E. coli isolates was in-
creased, and abundance of the tetracycline resistance de-
terminant tet(M) was elevated following heavy metal
supplementation [180]. In a study combining tylosin
(Tylan, Elanco; 0 or 10 mg/kg in-feed) with copper
(CuSO4; 10 or 100 mg/kg in-feed), Amachawadi et al.
[181] investigated fecal Enterococcus spp. to determine if
elevated copper supplementation co-selects for macro-
lide resistance. The transferable copper resistance gene
tcrB was identified in 8.5% of Enterococcus from ele-
vated copper- and tylosin-fed cattle, compared to copper
alone (4.5%), tylosin alone (3.5%), or the low copper/no
tylosin control (2.0%) [181, 182]. All the tcrB-positive
isolates proved to be E. faecium, and interestingly, all
tcrB-positive isolates harbored tetracycline tet(M) and
erythromycin resistance erm(B) determinants [181]. The
authors concluded that elevated dietary copper could
co-select for AMR in feedlot cattle [181]. Thus, heavy
metal supplementation should also be considered as a
selective pressure with the potential to promote the dis-
semination AMR determinants, and is a practice that
likely needs to be revisited as these minerals may be
added to the diet in excess of the animal’s requirement.
The bovine resistome & the wider environment
The primary concern relating to antimicrobials in agri-
culture is the potential for AMR determinants to expand
and spread via the food chain. Although urban lifestyles
rarely bring people into direct contact with livestock, the
animal production continuum extensively connects with
numerous industries, infrastructure, and ecologies. For
example, manure from antimicrobial-treated animals
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may be applied to crops, or waste from farms may drain
into rivers, reservoirs, and wastewater treatment plants.
In the US, cattle produce between 0.86 and 6.4 million t
of manure daily [183]. AMR can thus be transferred to
the wider environment, increasing the risk of contact
with a human pathogen. At present, knowledge about
the identity, diversity, distribution, and patterns of co-
resistance in beef-related AMR genes, and how they
compare to determinants in other ecosystems is scarce,
due in part to the difficulty in defining the bovine resis-
tome in the context of the larger environmental resis-
tome. AMR genes are widely present in both pristine
and human-impacted environments [184], so the occur-
rence of AMR in any specific biome does not necessarily
validate the impact of antimicrobial usage. However,
with the advent of next-generation sequencing and total
metagenomics, and resources like ARDB, and CARD
(the Comprehensive Antibiotic Resistance Database;
[185]), high-throughput AMR gene profiling resistomics
is shedding light on these relationships.
Resistome characterization via shotgun metagenomics
Noyes et al. [186] examined AMR genes of 1,741 beef
cattle as they moved longitudinally through the produc-
tion chain, characterizing feedlot, slaughter, and beef
product resistomes via shotgun metagenomics per-
formed on the Illumina HiSeq platform, and assessed
against the Resfinder [187], ARG-ANNOT [188], and
CARD [185] AMR gene databases. This identified 300
unique AMR genes, and showed that, the diversity of
the AMR genes decreased while cattle were in the feed-
lot, indicative of selective pressure imposed by antimi-
crobials, consistent with other studies showing diversity
reduction following antimicrobial exposure [163]. Exam-
ination of post-slaughter samples obtained from belts
and tables in the slaughterhouse, meat trimmings, and
market-ready samples revealed no AMR genes [186].
The authors concluded that effective practices at slaugh-
ter minimized the likelihood of AMR gene being passed
through the food chain. However, the high prevalence of
bovine DNA complicates shotgun metagenomics and
may result in low sensitivity of AMR gene detection.
Despite this, this study exemplifies the powerful utility
of metagenomic approaches in the study of AMR gene
ecology.
Metagenomics have also proved useful in the examin-
ation of AMR genes found in wastewater treatment
plants associated with tanneries and slaughterhouses.
Wastewater treatment plants are thought to be HGT
hotspots because of high bacterial diversity and density
[189, 190]. Wang et al. [191] profiled AMR genes and
MGEs in wastewater sludge from a Chinese leather tan-
nery via Illumina HiSeq and assessment with MG-RAST
[168] and ARDB [166]. Proteobacteria were most-
prevalent in anaerobic and aerobic sludge accounting for
35.95 and 58.36% of annotated reads, respectively,
followed by Firmicutes (16.31 and 6.08%, respectively)
[191]. Concerning AMR genes 747 reads (0.0081%) and
877 reads (0.0101%) in anaerobic and aerobic sludge, re-
spectively, were assigned to 54 and 42 types of known
AMR genes [191]. MDR efflux transporters were most
common, followed by tetracycline and sulfonamide re-
sistance genes (>20% of AMR-associated reads) [191].
The authors also detected MGEs in tannery DNA sam-
ples, but limitations in methodology restricted investi-
gating linkages with AMR genes. Taking a similar
approach, Li et al. [192] examined the resistome of plas-
mids harvested from influent, activated sludge, and
digested sludge of two Hong Kong wastewater treatment
plants receiving domestic and slaughterhouse (cattle and
other production animals) sewage. AMR genes were de-
tected in all of the plasmid metagenomes: the most
abundant were tetracycline resistance genes (29% of all
AMR gene sequences), quinolone resistance genes
(17%), and β-lactam resistance genes (12%) [192]. The
AMR gene distribution and abundance in each wastewa-
ter treatment plant sample is shown Fig. 3b, in circular
relationship format [192, 193]. This plasmid-centric
study highlights the mobile resistome and plasmid fates
more so than a total metagenome study, and future ex-
periments could involve comparisons between plasmid
and total resistomes to explore HGT of AMR determi-
nants. This paper also highlights a methodology to
examine MGE-associated AMR genes that is not con-
founded by environmental AMR genes or host DNA
contamination.
Resistome characterization via functional metagenomic
library screening
Sequence-based metagenomic AMR gene profiling is
also limited to those genes with similarity to already
known AMR genes, and metagenomic shotgun read
lengths present difficulties for the characterization of the
AMR genomic context. Functional metagenomic library-
based approaches have proved to be complementary in
the identification, quantification, and characterization of
novel resistance determinants. Wichmann et al. [194]
examined the resistome of dairy cow manure with
large-insert (>35 kb) fosmid libraries constructed from
5 manure samples. The resulting E. coli-based librar-
ies (containing 25.9 Gb of DNA) were screened for
resistance to kanamycin, chloramphenicol, tetracyc-
line, and the β-lactams carbenicillin (penicillin) and
ceftazidime (cephalosporin). Of 87 AMR E. coli clones
with genes conferring resistance to at least one of the
antimicrobials tested, 80 carried unique AMR genes,
suggesting that the cow microbiome harbors AMR
genes that are unique or unidentified elsewhere. A
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novel clade of chloramphenicol acetyltransferases was
also described [194]. Flanking sequence analysis indi-
cated that the AMR determinants originated from
typical cattle microbes: Firmicutes were predominant
(50% of sequenced clones), followed by Bacteroidetes
(23%) and Proteobacteria (14%) [194]. Another
powerful advantage of the fosmid library approach is
the ability to examine AMR gene context: i.e. co-
occurrence with other AMR genes, or association with
MGEs. Wichmann et al. found 2 kanamycin-resistant E.
coli clones with >5 putative genes with predicted AMR or
MGE functions [194]. Thus, library-based functional
metagenomic approaches combined with next-generation
sequencing are a powerful way to screen for AMR deter-
minants associated with MGEs, plasmids, or phages [195].
Linking antimicrobial use in beef production to
human health risk
Assessing the differential risk, importance, and source of
AMR genes
Given the ubiquity of AMR determinants in bovine and
other microbial communities, it is difficult to appraise
the relative risk any particular determinant presents for
the likelihood of transfer into a human pathogen and
clinical therapy failure. Confounding the issue are AMR
determinants that are expressed or silent in different
hosts, as well as AMR determinants akin to housekeep-
ing genes [196]. For the latter, ‘decontextualized’ house-
keeping genes, such as those harbored on MGEs, pose a
greater risk [1, 197]. Prioritizing the differential human
health risk posed by an AMR gene is complicated by
such issues, but risk ranking schemes have been
discussed [1, 198, 199]. Greatest risk may be presented
by AMR genes already hosted on MGEs in human
pathogens, and known to cause therapy failure. An ex-
ample of this is the recently detected plasmid-mediated
colistin (polymyxin E) resistance gene (mcr-1) in E. coli
isolates from poultry, swine, and infected humans [200,
201]. A beef-related example is the ~38 kb R plasmid
found in S. enterica serotype Newport, which confers
resistance to tetracycline, ampicillin, and carbenicillin
[202]. This caused severe penicillin-unresponsive sal-
monellosis linked to contaminated hamburger meat
[202]. The next level of risk may be from functional
AMR genes conferring resistance to human antimicro-
bials, but which are hosted in MGEs in non-pathogenic
bacteria. These might include the AMR determinants
encoded by ICEPmu1 and ICEMh1 found in P. multo-
cida and M. haemolytica, respectively [103, 104]. Ele-
vated risk is credited to MGEs because the acquisition
and selection of an AMR determinant in a MGE might
be the initial step for transmission to a human pathogen.
In the future, more focus should be devoted to AMR in
the context of MGEs, particularly for total resistome
studies utilizing libraries and shotgun metagenomics, or
emerging long-read sequencing technologies.
An example of risk and source determination may be
given by the long-term global epidemics of ground beef-
associated MDR S. enterica serotype Typhimurium
phage type DT104, which may express resistance to
ampicillin, chloramphenicol, streptomycin, sulfameth-
oxazole, and tetracycline (resistance-type ACSSuT)
[203–205]. In some isolates, these AMR genes are
hosted in a 13 kb MDR region, residing in a larger
chromosome-encoded ~43 kb region called Salmonella
genomic island 1 (SGI1). The MDR region harbors Class
I integrons—genetic elements capable of consolidating
multiple AMR gene cassettes [206]. Integrons are often
found in conjunction with MGEs; in the case of DT104,
HGT can occur via phage-mediated transfer [207]. Al-
though veterinary antimicrobial usage and food animals
have long been the chief culprit for the origin and dis-
semination of DT104, Mather et al. [208, 209] chal-
lenged the perception that DT104 originated from a
single zoonotic population by whole-genome sequencing
Scottish DT104 collections. In total, 135 isolates from
humans and 83 from cattle were sequenced and com-
pared against 111 other DT104 isolates from diverse
host animals and countries. Using phylogenetic diffusion
models, the authors found that AMR DT104 populations
were distinguishable between cattle and humans, and
that animal-to-human and human-to-animal transitions
were rare, and occurred at the same frequency [209].
This suggested that most human infections were unlikely
to originate from the local cattle. AMR diversity was
greater in human isolates, resulting from multiple,
independent recombination events in SGI1’s MDR re-
gion [209]. In part, this suggested that most human in-
fections were acquired from humans, and that DT104
circulated separately in the animal and human populations,
and/or unique sources infected humans vs. animals [209].
Mather et al. emphasized the importance of integrating
veterinary and clinical data to make evidence-based
judgments concerning the sources of AMR infections.
Direct evidence of human health impact of beef
antimicrobial usage
Linking on-farm antimicrobial use to human infection is
difficult. While antimicrobial usage evidently selects for
drug-resistant organisms, there is a gap in knowledge
connecting usage to the flow of AMR determinants from
the bovine microbiota to outbreaks of human AMR
diseases. To bridge this gap, a number of studies com-
pared outbreak clinical isolates to animal isolates taken
at similar times from nearby locations [210–212]. Typic-
ally, isolates were examined for similar AMR/genetic
profiles, and if identical, this provided some evidence of
the AMR outbreak source. Direct links to specific
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antimicrobial usage is rarely identified for outbreaks. A
caveat of many studies is that transfer is assumed to be
from cattle to humans, or remains unknown. Several
AMR E. coli and Salmonella outbreaks have been associ-
ated with beef [213–215], but there are few examples
where those AMR determinants have been traced back
to AMR bacteria in cattle [210]. This reinforces the need
for greater integration of human and veterinary data.
For beef production, tracing the source of an AMR out-
break is complicated by system complexity, herd move-
ment, and lack of industry motivation. And although
beef production is a major industry, more focus has been
on the human health impact of AMR transfer in dairy
cattle, and in the swine and poultry industries (reviewed
in [214]). Dairy-related outbreaks may be easier to docu-
ment because the source animal population is main-
tained, whereas the beef, swine, and poultry populations
are consumed. Selected examples of outbreaks and
human health threats posed by bovine AMR bacteria
are listed in Table 2. These demonstrate that the
most convincing molecular and epidemiological AMR
links are found when the infected human is directly
connected to the animal population on farms or via
farm workers [211, 216, 217]. Direct exposure to live-
stock is a known risk factor for zoonotic transmission
(reviewed in [218]).
Conclusions & future focus
As in most environments, AMR determinants exist ubi-
quitously in the beef production biome, regardless of
antimicrobial exposure. Nevertheless, the use of antimi-
crobials for bovine welfare and growth promotion con-
tributes selective pressure that increases the abundance
of AMR genes and their host bacteria, and promotes the
genesis and dissemination of MDR organisms. The pres-
ence or absence of connections between AMR in bovine
microbial populations to human health threats are likely
to become clearer with the increasing application of
whole-genome sequencing and metagenomic resis-
tomics. The role of MGEs in AMR propagation is likely
to be an important focus for understanding the impact
of veterinary antimicrobials. Future investigations may
validate mitigation strategies, such as the separation of
antimicrobials for use in beef cattle from those used in
humans. Proper and judicious use of antimicrobials will
help prolong the usefulness of both clinical and veterin-
ary antimicrobials, but ever-increasing usage of anti-
microbials in food-animal production suggests that
microbes will only continue to acquire resistance. Of
particular concern for cattle are the MDR BRD agents:
in the future, respiratory infections may become untreat-
able with current antimicrobials. On a positive note, sev-
eral studies reveal that adequate hygiene and appropriate
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treatment at slaughterhouse and wastewater treatment
facilities are efficacious at reducing or eliminating trans-
mission of AMR organisms and genes. Thus, such
procedures and facilities should be explored further, and
promoted in deficient areas of food-animal production.
Methods
Literature search
The literature search was conducted from January to
March 2016 via Google Scholar and PubMed. Recent
(2012-present) studies that described AMR or usage in
context with beef production, bovine pathogens, com-
mensal bacteria, metagenomics, the resistome, and cattle
were included. Older reports, or studies referring to
dairy operations were excluded, except for where beef
production information was sparse.
Comparison of most frequently reported AMR in bovine
pathogens
A literature search was conducted for AMR in bovine
pathogens. Journal articles ([30–88], 2000-present) were
collected if the AMR data was presented in a format
conducive to comparison. Reports that determined the
percentage of resistant isolates in a larger collection of
isolates were considered. Reports were not considered if
the collection of isolates had been pre-screened or
enriched for resistance to any antimicrobial. The percent
resistance value (i.e. number of resistant isolates compared
to the total number of isolates) for each antimicrobial
tested and for each strain was recorded. Journal articles
that did not provide resistant, intermediate, or susceptible
determinations were excluded. Intermediate resistance
was not included in the percent resistance. For several
antimicrobials/species, the percent resistance was given by
author-determined values; in many cases, resistance was
determined according to standardized interpretive criteria.
The median of the percent of resistant isolates was
calculated, and the resulting median value is proportional
to the diameter of each circle in Fig. 2.
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